Chinese Academy of Sciences

Shanghai United Imaging Healthcare Co., Ltd.

Shanghai Institute of Materia Medica, Cas

Shanghai Lead Discovery Pharmaceuticals Limited Company

Jianhua Shen

Hualiang Jiang

Xiaodong Wang

Yanen Guo

Kai Wang

Wenwei Xu

Yiping Wang

Xinde Chen

Jing Lan Chen

Hong Tao Liu

Fei Ye

Kaixian Chen

Junhua Chen

Jingkang Shen

Tao Sun

Jianping Zuo

Xiaomin Luo

Xu Shen

Bing Xiong

Bin Dai

Lili Chen

Haibin Luo

Donglu Bai

Yiming Yang

Changlin Mei

Yangliang Ye

Xishan Xiong

Jing Tang

Lili Fu

Ying Leng

Chunshan Gui

Yifu Yang

Xianhan Zhuang

Xuchang He

The present disclosure relates to an image processing method. The method may include: obtaining image data; reconstructing an image based on the image data, the image including one or more first edges; obtaining a model, the model including one or more second edges corresponding to the one or more first edges; matching the model and the image; and adjusting the one or more second edges of the model based on the one or more first edges.

Systems and methods for image segmentation

The present invention relates to pyrimidone compounds used as Lp-PLAinhibitors and pharmaceutical compositions thereof. The structure of the pyrimidone compounds is represented by general formula (I), wherein R, R, R, X, Ar, Y and n are defined as in the specification and claims. The compounds of general formula (I) in the present invention, stereoisomers and pharmaceutically acceptable salts thereof can be used as Lp-PLAinhibitors for preventing, treating and/or ameliorating diseases associated with the activity of Lp-PLAenzyme. 

Pyrimidone compounds used as Lp-PLAinhibitors and pharmaceutical compositions thereof

The present disclosure discloses a method for generating color medical image. The method for generating color medical image comprising: acquiring medical image data, segmenting at least one tissue in the medical image data, determining a combined color table from a combined color table database based on the at least one tissue; and generating a color medical image based on the combined color table. In some embodiments, the combined color table comprises data of color schemes for the segmented tissues.

Method and system for generating color medical image based on combined color table

A method for image segmentation may include acquiring an image including a region of interest (ROI). The ROI has a first margin, the ROI includes a subregion, and the subregion has a second margin. The method may further include acquiring a first model according to the ROI, wherein the first model has a third margin. The method may further determine, based on the first margin and the third margin, a second model by matching the first model with the image, wherein the second model includes a sub-model, and the sub-model has a fourth margin. The method may further include determining, based on the second margin, a third model by adjusting the fourth margin of the sub-model in the second model. The method may further include segmenting the ROI according to the third model and generating a segmented ROI based on a result of the segmentation.

Systems and methods for image processing

Pyrimidone compounds used as Lp-PLA2 inhibitors and pharmaceutical compositions thereof

The present invention disclosed compounds of Structural Formula (I), and enantiomer, racemic body, pharmaceutically acceptable salts, solvates or hydrates thereof, wherein variable groups are as defined within, as well as methods for preparing such compounds. The compounds are useful as PPAR&#x3b3; agonist, through activating PPAR-RXR heterodimers that interacts with specific DNA response elements within promoter regions of target gene, particularly in the treatment and prevention of polycystic kidney and cancer. 

Pyrimidinyl-propionic acid derivatives and their use as PPAR agonists

The invention discloses a new use of a class of heptacyclic compounds in the preparation of formulations for the prevention and treatment of diabetes and metabolic syndromes; the present invention also discloses a new class of heptacyclic compounds; the present invention also discloses a process for preparing the heptacyclic compounds and a composition containing the same. The heptacyclic compounds of the present invention can be used to effectively preventing or treating diseases such as diabetes and metabolic syndromes. 

Heptacyclic compounds and the pharmaceutical uses thereof for preventing and treating diabetes and metabolic syndrome

The present invention discloses 3D-structure of SARS-CoV Viral 3CL Protease obtained through molecular simulation. The 3D-structure is used as a drug target for screening the existing medical database CMC (Comprehensive Medicinal Chemistry, MDL Information System, Inc.), and a group of compounds which have the activity of inhibiting SARS-CoV virus 3CL Protease are found. Cinanserin was tested at molecular and viral levels, and it was found to be able to inhibit the SARS-CoV viral 3CL protease and SARS-CoV viruses. Cinanserin analogs were synthesized and tested at molecular and viral levels, they were found to be able to inhibit the SARS-CoV virus 3CL Protease and SARS-CoV viruses, and may be used for treating and/or preventing SARS-CoV virus infection.

3D-structure model of SARS coronavirus 3CL protease and anti-SARS drugs

Growing community of inventors

Shanghai, China

Jianhua Shen